Cybin Inc
Change company Symbol lookup
Select an option...
CYBN Cybin Inc
TYGO Tigo Energy Inc
ERAS Erasca Inc
MEOH Methanex Corp
CADL Candel Therapeutics Inc
YECO Yulong Eco-Materials Ltd
ZVOI Zovio Inc
YEXT Yext Inc
ZNOG Zion Oil and Gas Inc
PM Philip Morris International Inc

Health Care : Pharmaceuticals | Small Cap Value
Based in Canada
Company profile

Cybin Inc. (Cybin) is a clinical-stage biopharmaceutical company. The Company is engaged in creating psychedelic-based therapeutics to address the unmet need for new treatment options for people who suffer from mental health conditions. Its development pipeline consists of deuterated psilocybin analog program (CYB003), deuterated dimethyltryptamine program (CYB004), phenethylamine derivatives program (CYB005), and technology programs. The Company is engaged in developing CYB003, a deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The Company's CYB005 is focused on the development of therapeutic phenethylamine derivatives for the treatment of potential neuroinflammation and other neurological conditions. Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands, and Ireland.


Last Trade
0.0033 (1.38%)
B/A Size

Market Hours

Closing Price
Day's Change
-0.0122 (-4.84%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:
Latest Earnings Met Consensus (Q3 ending 12/2022)Next Earnings Announcement
Announced February 16, 2023
-$0.04Q3 Estimate range
of 5 analysts
-$0.06 to -$0.03Q4 Earnings
will announce
(Unconfirmed) June 22, 2023

Quarterly Earnings History and Estimates

Hide high-low estimates
Draw trendlines

Draw up to 3 lines inside the chart.



CYBN's fiscal year ends in March

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.